Mesenchymal stem cell carriers enhance antitumor efficacy induced by oncolytic reovirus in acute myeloid leukemia

Wang, Xianyao; Yang, Yichen; Wang, Nianxue; Wu, Xijun; Xu, Jianwei; Zhou, Yanhua; Zhao, Xing; He, Zhisong

doi:10.1016/j.intimp.2021.107437

Cited by 9 publications

(3 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that ReoT3D and MSCs together were more effective for therapy than ReoT3D and MSCs alone [ 191 ]. Wang et al demonstrated that Human UC-MSCs harboring reovirus display antitumor effectiveness impacts for AML in the presence of Nabs via increasing CXCL10 production from hUC-MSCs [ 193 ] (Table 1 ).…”

Section: Msc-based Delivery Of Oncolytic Reovirusmentioning

confidence: 99%

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

et al. 2023

View full text Add to dashboard Cite

Oncolytic viruses (OVs) infect, multiply, and finally remove tumor cells selectively, causing no damage to normal cells in the process. Because of their specific features, such as, the ability to induce immunogenic cell death and to contain curative transgenes in their genomes, OVs have attracted attention as candidates to be utilized in cooperation with immunotherapies for cancer treatment. This treatment takes advantage of most tumor cells' inherent tendency to be infected by certain OVs and both innate and adaptive immune responses are elicited by OV infection and oncolysis. OVs can also modulate tumor microenvironment and boost anti-tumor immune responses. Mesenchymal stem cells (MSC) are gathering interest as promising anti-cancer treatments with the ability to address a wide range of cancers. MSCs exhibit tumor-trophic migration characteristics, allowing them to be used as delivery vehicles for successful, targeted treatment of isolated tumors and metastatic malignancies. Preclinical and clinical research were reviewed in this study to discuss using MSC-released OVs as a novel method for the treatment of cancer.

show abstract

Section: Msc-based Delivery Of Oncolytic Reovirusmentioning

confidence: 99%

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

et al. 2023

View full text Add to dashboard Cite

show abstract

“…MSCs with measles virus have shown promise and delivery to the tumor bed in clinical trials (NCT02068749). OV-infected carrier cells have demonstrated enhanced migratory properties and secretion of proinflammatory cytokines, for example, human umbilical cord MSCs, suggesting that they can enhance the antitumor efficacy of virotherapy [ 110 ]. Apart from MSCs, neural stem cells (NSCs) also improved the delivery of OV in multiple cancer models [ 111 , 112 , 113 ].…”

Section: Combination Therapy With Oncolytic Virusmentioning

confidence: 99%

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy

Rahman

McFadden

2021

Cancers

View full text Add to dashboard Cite

Cancer remains a leading cause of death worldwide. Despite many signs of progress, currently available cancer treatments often do not provide desired outcomes for too many cancers. Therefore, newer and more effective therapeutic approaches are needed. Oncolytic viruses (OVs) have emerged as a novel cancer treatment modality, which selectively targets and kills cancer cells while sparing normal ones. In the past several decades, many different OV candidates have been developed and tested in both laboratory settings as well as in cancer patient clinical trials. Many approaches have been taken to overcome the limitations of OVs, including engineering OVs to selectively activate anti-tumor immune responses. However, newer approaches like the combination of OVs with current immunotherapies to convert “immune-cold” tumors to “immune-hot” will almost certainly improve the potency of OVs. Here, we discuss strategies that are explored to further improve oncolytic virotherapy.

show abstract

“…It has been reported that AML‐MSCs enable the abilities of multiple lineage differentiation, rapid cell proliferation, self‐renewal, and release of high amounts of cytokines and growth factors. 5 De novo AML‐MSCs display a significant increase in the expression levels of vascular endothelial growth factor (VEGF), stromal cell‐derived factor 1 (CXCL‐12), Receptor of prostaglandin E2 (RPGE‐2), indoleamine 2,3‐dioxygenase, IL‐1β, IL‐6, and IL‐32 compared to HMSCs. 6 Multiple cytokines, especially IL‐6 and IL‐8, have been shown to support chemoresistance in AML.…”

Section: Introductionmentioning

confidence: 99%

Acute myeloid leukemia (AML)‐derived mesenchymal stem cells induce chemoresistance and epithelial–mesenchymal transition‐like program in AML through IL‐6/JAK2/STAT3 signaling

Dong

Zhang

et al. 2023

Cancer Science

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) has a high rate of treatment failure due to increased prevalence of therapy resistance. Mesenchymal stem cells (MSCs) in the leukemia microenvironment contribute to chemoresistance in AML, but the specific mechanism remains unclear. The critical role of the epithelial-mesenchymal transition (EMT)-like profile in AML chemoresistance has been gradually recognized. However, there is no research to suggest that the AML-derived bone marrow mesenchymal stem cells

show abstract

Mesenchymal stem cell carriers enhance antitumor efficacy induced by oncolytic reovirus in acute myeloid leukemia

Cited by 9 publications

References 61 publications

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy

Acute myeloid leukemia (AML)‐derived mesenchymal stem cells induce chemoresistance and epithelial–mesenchymal transition‐like program in AML through IL‐6/JAK2/STAT3 signaling

Contact Info

Product

Resources

About